CELL DEATH DIS 润色咨询

Cell Death & Disease

出版年份：2010 年文章数：6499 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：2.8% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2024-04-16 Judy Bright 来自广东省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：肺癌;肿瘤生物学
    经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏
    时间线变化如下：
    2024.01.25：Submission
    2024.01.26：Under Consideration，Editor not Assigned
    2024.02.15：Editor Assigned
    2024.04.09：Decision Made
    2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回
    目前正在狂补实验，攒攒人品🙏🙏🙏
    顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T)

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2023-04-06 123f51aam86(暂无昵称) 来自陕西省

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~

    23

    展开23条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2024-03-25 124a8810m95(暂无昵称) 来自重庆

    偏重的研究方向：肿瘤
    经验分享：小cdd好还是cancer letters好？

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2023-08-25 1245a556m23暂无昵称 来自河南省

    从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？

    17

    展开17条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2024-01-16 ms4000000731438466 来自天津

    偏重的研究方向：肿瘤
    经验分享：提交10天，显示状态为Decision made什么情况？

    7

    展开7条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2023-05-18 36192448 来自湖南省

    偏重的研究方向：细胞死亡
    经验分享：一审65天了，还没消息，彻底躺平了

    12

    展开12条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2023-07-07 36192448 来自湖南省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：干细胞;细胞死亡
    经验分享：一审84天，二审7天，目前decision made 7天还没消息

    9

    展开9条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2022-07-12 ms9000001463682571

    4月12投稿
    4月13检查格式通过
    4月20指定责编
    4月23送外审
    4月25有审稿人同意审稿
    5月4号审稿结束，开始决定意见
    5月16日发邮件告知修回意见
    7月7日修回
    7月8日核对格式
    7月9日决定意见
    7月11日原则性接收，核对格式
    7月12日正式接收

    22

    展开22条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2024-02-06 ms3000001660419742 来自台湾省

    偏重的研究方向：幹細胞
    经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ

    5

    展开5条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2198868, encodeId=84d9219886842, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肺癌;肿瘤生物学<br>经验分享：从投稿到目前一审回来一共81天，给了 minor revision，目前在狂补实验，希望后面能顺利🙏<br>时间线变化如下：<br>2024.01.25：Submission<br>2024.01.26：Under Consideration，Editor not Assigned<br>2024.02.15：Editor Assigned<br>2024.04.09：Decision Made<br>2024.04.15：出现一个空的进度条，然后当天晚上收到了小修的邮件，给了三周时间修回<br>目前正在狂补实验，攒攒人品🙏🙏🙏<br>顺便问一下，这个期刊小修的话二审会送外审吗？着急毕业 (T_T), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Apr 16 23:30:16 CST 2024, time=2024-04-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124046, encodeId=6a3121240465b, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：从CDD转投过来的，投稿后3天状态变成under consideration，等待3周未分配编辑，催稿了一次，回复目前稿件太多，第29天分配编辑，然后出现Zip of files for Reviewer，目前仍是under consideration，过来沾沾各位大神的运气~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e6f2450981, createdName=123f51aam86(暂无昵称), createdTime=Thu Apr 06 10:11:01 CST 2023, time=2023-04-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2195207, encodeId=bf68219520e47, content=偏重的研究方向：肿瘤<br>经验分享：小cdd好还是cancer letters好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Mon Mar 25 13:13:11 CST 2024, time=2024-03-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤<br>经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡<br>经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：干细胞;细胞死亡<br>经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿<br>4月13检查格式通过<br>4月20指定责编<br>4月23送外审<br>4月25有审稿人同意审稿<br>5月4号审稿结束，开始决定意见<br>5月16日发邮件告知修回意见<br>7月7日修回<br>7月8日核对格式<br>7月9日决定意见<br>7月11日原则性接收，核对格式<br>7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞<br>经验分享：1/11 投稿 還沒有editor assigned，祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡<br>经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省)]
    2023-07-01 Shawnwang 来自广东省

    偏重的研究方向：细胞死亡
    经验分享：刚刚submit，上帝保佑，沾沾大家的喜气

    10

    展开10条回复
共500条页码: 2/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分